Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial (2018)
- Autor:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1002/clc.22882
- Subjects: TERAPIA BIOLÓGICA; ESTUDOS RANDOMIZADOS; INFARTO DO MIOCÁRDIO; BETA-BLOQUEADORES
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Clinical cardiology
- ISSN: 0160-9289
- Volume/Número/Paginação/Ano: v. 41, n. 3, p. 392-399, 2018
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
NICOLAU, Jose Carlos. Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial. Clinical cardiology, v. 41, n. 3, p. 392-399, 2018Tradução . . Disponível em: https://doi.org/10.1002/clc.22882. Acesso em: 19 abr. 2024. -
APA
Nicolau, J. C. (2018). Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial. Clinical cardiology, 41( 3), 392-399. doi:10.1002/clc.22882 -
NLM
Nicolau JC. Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial [Internet]. Clinical cardiology. 2018 ; 41( 3): 392-399.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1002/clc.22882 -
Vancouver
Nicolau JC. Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial [Internet]. Clinical cardiology. 2018 ; 41( 3): 392-399.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1002/clc.22882 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1002/clc.22882 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
